发明名称 Maintenance of platelet inhibition during antiplatelet therapy
摘要 A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
申请公布号 US8759316(B2) 申请公布日期 2014.06.24
申请号 US201313931384 申请日期 2013.06.28
申请人 The Medicines Company 发明人 Ruderman Chen Lisa;Skerjanec Simona;Bell Dawn;Prats Jayne;Todd Meredith;Arculus-Meanwell Clive Arthur;Mould Diane
分类号 A61K31/70;C07H19/00;C07H19/04;C07H19/10;C07H19/20 主分类号 A61K31/70
代理机构 Frommer Lawrence & Haug LLP 代理人 Frommer Lawrence & Haug LLP ;Kuzmich, Esq. Sandra;Garman, Esq. Russell A.
主权项 1. A method of transitioning a patient in need thereof from administration of cangrelor during percutaneous coronary intervention (PCI) to administration of cangrelor in preparation for surgery, the method comprising: (1) administering a PCI dosing regimen, wherein the PCI dosing regimen comprises (i) administering intravenously a 30 μg/kg bolus of cangrelor before the start of PCI; and (ii) administering intravenously a continuous infusion of cangrelor at an infusion rate of 4 μg/kg/min after administration of the bolus; (2) discontinuing the administration of the PCI dosing regimen; and (3) administering a bridge dosing regimen, wherein the bridge dosing regimen comprises administering intravenously a continuous infusion of cangrelor at an infusion rate of 0.75 μg/kg/min.
地址 Parsippany NJ US